Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$2.17 USD
-0.05 (-2.25%)
Updated Jun 14, 2024 11:05 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 61 - 80 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; UPLIFT Registration Study Continues to Enroll Patients; UP-NEXT Study to Initiate Next Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-2056 Preclinical Data Presented and Target Disclosed at NCI-AACR-EORTC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expansion Study Update Confirms Prior Data, Supports UPLIFT Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Innovative Platforms Could Offer an Advantage in the ADC Market; Initiate Buy with $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Can UpRi Put the Bling back into Platinum Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D